Feed PALI
PA

Palisade Bio, Inc.

PALI · NASDAQ

$1.59 -5.36% (-$0.09)
1M -24.29%
Market Cap $348.9M
P/E Ratio -
Div. Yield -
ROE 33.47%

Bulios Fair Price

$1.14

28.3% downside

Trenutna cena

$1.59

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica PALI trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
4/9
Valuation
35 /100
Fair
P/B 2.87x
P/S 697.79x
PEG N/A
Growth
100 /100
Growing
Book val. growth 118.05%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak
FCF margin 3,638.00%
Op. margin 7,069.80%
Gross margin 100.00%
Quality
0 /100
Poor
Asset turnover 0.00x
ROA 25.09%
ROIC 28.96%
Debt
69 /100
Low
Current ratio 24.26x
Int. coverage -5,536.67x
Debt/Equity 0.00x
Stability
11 /100
Unstable
EPS volatility 84.41%
Profitable years 0
Beta 1.55x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o PALI
Online

O podjetju

Palisade Bio, Inc. (PALI) is a biotechnology company focused on the development of novel drugs and therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders. The company is developing drugs and therapies that have the potential to alleviate health issues and improve the quality of life for patients suffering from these conditions. Palisade Bio emphasizes innovation and utilizes modern technologies and scientific knowledge to discover new treatment options. Their goal is to bring new drugs and therapies to the market that can make a real difference and enhance patient care. Palisade Bio is actively involved in research and clinical studies to confirm the effectiveness and safety of their products. Palisade Bio, Inc. (PALI) shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focusing on innovative therapeutic approaches in the field of gastrointestinal diseases and rare metabolic disorders.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

J. D. Finley

Employees

14

Headquarters

Denver

Prihajajoči dogodki

09 NOV.

Earnings

Upcoming earnings report

50d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.